General Motors
BP
Ford Motor Company
AstraZeneca
DaimlerChrysler
CNN
General Electric
US Senate
Credit Suisse First Boston
Volkswagen
Siemens
Philip Morris
Bloomberg
Britvic Softdrinks
Verizon
AT&T
Nestle
FIAT
Nestle
3
AstraZeneca
General Dynamics
Hewlett Packard
ABN Amro
UBS Warburg
Merrill Lynch
New York Stock Exchange
The Economist
France Telecom
T-Mobile
Danske Bank
US Department of Defense
Boeing
Lafarge
US State Department
Safeway
People's Republic of China's
Ministry of Agriculture
Nordea
Tesco
Royal & SunAlliance
Pfizer
Philips
Philips
Sybase
Sprint
New York Life Insurance
Canon USA
Novell
Siemens
Ericsson
EDS
Philip Morris International
Royal & SunAlliance
Novartis
Philips
Credit Lyonnais
Nestle
UK Department of Trade & Industry
Sun Microsystems
British American Tobacco
Norsk Hydro
AstraZeneca
Skanska
BAE Systems
Kodak
The Royal Mail Group
Henkel
Bank of Montreal
Danske Bank
BMW
Kronos Corporation
HM Revenue & Customs
Fujitsu Technology Services
Zurich Financial Services
Halliburton
BBC
General Motors
Blue Cross/Blue Shield of Massachusetts
T-Mobile
AT&T
MOL
AstraZeneca
Channel 4 Corporation
VHA
Burges Salmon
Motorola
British Telecom
Ferrari
Deloitte & Touche
PA Consulting
BP
US Department of Defense
US Army
UK Department of Trade & Industry
EMC Corporation
US Department of Commerce
Encana Corporation
IEEE
3
Ericsson
Hewitt Associates LLC
HEALTHvision
Paramount
Lexmark
US Department of Defense
JD Edwards
Ingersoll-Rand
PricewaterhouseCoopers
US State Department
Vodafone Omnitel
Nomura
US State Department
UK Department of Trade & Industry
Reed Elsevier
Dow Chemical Company
General Electric
General Motors
Siemens Power Generation
Macmillan Publishing
Texas Instruments
Forrester Research
Henkel
McData
Philips
Wall Street Journal
Nestle
Lloyds
Philips
NASA
SCA
ABN Amro
Reuters
ITN
IBM NICA
Forbes.com
AstraZeneca
US Department of Commerce
Vodafone Omnitel
Nissan North America, Inc.
Toyota Motor
The McGraw-Hill Companies
Fox Sports
BBC
Society of Petroleum Engineers
US Department of Energy
Nestle
3
European Commission
AT&T
General Motors
Telecom Italia
Harrah's
Sun Microsystems
AXA
Sybase
Napster
Oracle
US State Department
Compuware
Olympus
ARM
AstraZeneca
Taylor & Francis
Hewlett Packard
Federal Express
Nissan Motor
The McGraw-Hill Companies
Milward Brown Precis
Federal Government of Canada
UK Home Office
HM Revenue & Customs
3
3
Harvard Business School
Lloyds
Britvic Softdrinks
MOL
Macmillan Publishing
3
Hewlett Packard
Allianz Life Insurance Co
Swiss Army
Ingersoll-Rand
Parliament of Singapore
VMS
3
Singapore Police Force
Sony Music
BP
GSA Advantage!
New York Life Insurance
Kaiser Permanente
Stanford Business School
Johns Hopkins
Wachovia
Ericsson
Standard Life Insurance
Credit Lyonnais
General Motors
Siemens
Sun Microsystems
Raytheon
AstraZeneca
Commerzbank
Allstate Insurance
AstraZeneca
State of Washington
Napa Valley County
Texas Department of Transportation
American HomePatient
TIBCO
Lloyds
Sharper Image
Xerox
America Online
BP
Pfizer
Lockheed Northrop Grumman
Lloyds
Dow Chemical Company
Sun Microsystems
Draeger Medical
Swiss Army
BBC
Sutter Health
Kenyan AIDS Clinic
University of Washington
State of Minnesota
World Wildlife Fund
Autonomy Group Customers
 
News
Events
RSS Feeds
Press Release Archives
For Financial News, please see the Investors section of the website.

News LEADING NORWEGIAN TR... | AUTONOMY CONGRATULAT... | OPEN TEXT INTRODUCES...
Press Release
Related Events
Related Case Studies
Related Resources

Autonomy Congratulates Isabel

Online clinical decision support and information system wins prestigious British Computer Society IT Award

CAMBRIDGE, UK- 6 November 2002- Autonomy Corporation plc (Nasdaq: AUTN; LSE: AU.; Nasdaq Europe: AUTN), is today delighted to congratulate the Isabel Medical Charity upon winning a British Computer Society Award for the innovative nature of its online clinical decision support system for medical professionals (ISABEL).

The British Computer Society IT Awards were created 30 years ago to honor excellence in the field of UK Information Technology. The awards seek to encompass projects of social benefit and business value to society at large, as well as outstanding technical achievement and innovative flair.

ISABEL, which was launched in June of this year, aims to bridge the knowledge gap that exists in many health systems, notably that most of the critical knowledge and experience resides with senior consultants in hospitals and not with the doctors who first examine patients. ISABEL provides free of charge critical support in areas such as diagnosis, treatment guidelines and shared experience. ISABEL, which currently concentrates on pediatrics, also offers an annotated image library, allowing users to compare their patients' visible symptoms with those available on the site, and consequently assist them in making a potentially life-saving diagnosis.

Autonomy donated its pattern-matching software to the Isabel Medical Charity to enable fast, accurate assistance for all medical professionals, who often do not have the benefit of the more specialist knowledge required to make accurate diagnoses. Applying Autonomy's pattern matching software to medical textbooks enables ISABEL to deliver a fast and practical differential diagnostic tool. When using ISABEL the doctor simply needs to type in a patient's symptoms from which the Autonomy software extracts the key ideas before searching ISABEL's extensive library of content to find a similar combination of symptoms - and consequently suggesting a range of relevant diagnoses. In essence, this mimics the doctor's existing and intuitive diagnostic process, the difference being that the system's base of textbook knowledge is far larger than can readily be stored in the human brain. Its performance is also unaffected by tiredness and overwork.

About ISABEL

Jason and Charlotte Maude founded the project in July 1999 together with Dr Joseph Britto, Pediatric Intensive Care Consultant at St Mary's Hospital, Paddington, London. Three months prior to this, the Maudes' 3-year-old daughter, Isabel, had spent a month in Intensive Care suffering multiple organ failure and cardiac arrest and a further month in a High Dependency ward. All this because her local A&E department and GP had failed to recognize her critical, life-threatening symptoms following chicken pox. Against all odds, Isabel's sole legacy is a large wound requiring extensive plastic surgery. During their time in hospital, the idea of a diagnostic tool slowly evolved during conversations between the Maudes and Dr Britto, who gradually gathered the support of a number of high profile doctors from hospitals around the country to make up the ISABEL team. The Isabel Medical Charity received charitable status in April 2000. Its registered office is in London. Further information is on the web at www.isabel.org.uk.

About Autonomy

Autonomy Corporation plc (Nasdaq: AUTN; Nasdaq Europe: AUTN; LSE: AU.) is a global leader in infrastructure software for the enterprise. Autonomy's technology powers applications dependent upon unstructured information including e-commerce, customer relationship management, knowledge management, enterprise information portals, enterprise resource planning and online publishing. Autonomy's customer base includes more than 575 global companies, including Hutchison 3G, Channel 4, Deutsche Bank, AT&T, AstraZeneca, BAE Systems, Ford, Ericsson, General Motors, Lucent, Royal Sun Alliance, Sun Microsystems and public sector agencies including the UK Government's Department of Trade and Industry, NASA, the US Department of Defense and the US Department of Energy. Strategic reseller and OEM partners include leading companies such as BEA, Business Objects, Computer Associates, Hewlett Packard, IBM Global Services, Oracle, Vignette and Sybase. The company has offices in North America, Europe, Asia and Australia and is on the Web at www.autonomy.com.

Caution Concerning Forward-Looking Statements

With the exception of historical information, the matters set forth in this news release are forward-looking statements that involve risks and uncertainties. A number of important factors could cause actual results to differ materially from those in the forward-looking statements. These factors include, among others, technology risks, including dependence on core technology; fluctuations in quarterly results; dependence on new product development; rapid technological and market change; reliance on sales by others; management of growth; dependence on key personnel; rapid expansion; growth of the Internet; financial risk management; and future growth subject to risks. These factors and other factors which could cause actual results to differ materially are also discussed in the company's filings with the United States Securities and Exchange Commission, including Autonomy's Annual Report on Form 20-F and Registration Statements on Form F-1.

For more information, please contact:
Ian Black
Autonomy Corporation plc
+44 (0) 1223 448 000
ianb@autonomy.com
Jason/Charlotte Maude
ISABEL Medical Charity
+44 (0) 208 748 4330
info@isabel.org.uk

This is a selection of our forthcoming events, please visit our seminars page for more information.

Automatic Hyperlinks provided by IDOL Server 7

This is a small selection of the Autonomy case studies available, please visit our publications site at http://publications.autonomy.com/ for more information.

Automatic Hyperlinks provided by IDOL Server 7

+1 415 243 9955

Company
Technology
Functionality
Products
Solutions
Services
Customers
Partners
News & Events